Why the study?
CAVS represents an increasing healthcare burden with no effective pharmacological therapies proven to halt or delay progression, making medical treatments an unmet clinical need.
Do pharmacological treatments halt or delay the progression of calcific aortic valve stenosis?
Do pharmacological treatments halt or delay the progression of calcific aortic valve stenosis?
This review highlights that despite ongoing research into lipid-lowering, vasoactive, and anti-calcific agents, aortic valve replacement remains the only effective option for severe calcific aortic valve stenosis.
Aortic valve replacement remains sole proven therapy for severe calcific aortic valve stenosis; leaves open targeted pharmacological trials.
Calcific aortic valve stenosis (CAVS), the most common heart valve disease, is characterized by the slow progressive fibro-calcific remodeling of the valve leaflets, leading to progressive obstruction to the blood flow. CAVS is an increasing health care burden and the development of an effective medical treatment is a major medical need. To date, no effective pharmacological therapies have proven to halt or delay its progression to the severe symptomatic stage and aortic valve replacement represents the only available option to improve clinical outcomes and to increase survival. In the present report, the current knowledge and latest advances in the medical management of patients with CAVS are summarized, placing emphasis on lipid-lowering agents, vasoactive drugs, and anti-calcific treatments. In addition, novel potential therapeutic targets recently identified and currently under investigation are reported.
No takes yet. Share an insight, caveat, or question.
Donato et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: